Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| West Nile virus | 11 | 2023 | 117 | 5.440 |
Why?
|
| West Nile Fever | 11 | 2023 | 139 | 5.320 |
Why?
|
| Fomites | 1 | 2021 | 5 | 0.750 |
Why?
|
| Appendicitis | 1 | 2022 | 129 | 0.730 |
Why?
|
| Pneumonia | 1 | 2024 | 325 | 0.700 |
Why?
|
| Cytokines | 2 | 2023 | 1284 | 0.630 |
Why?
|
| Neglected Diseases | 1 | 2021 | 147 | 0.600 |
Why?
|
| Triatoma | 3 | 2024 | 29 | 0.590 |
Why?
|
| Chagas Disease | 4 | 2024 | 286 | 0.580 |
Why?
|
| RNA, Viral | 4 | 2024 | 538 | 0.550 |
Why?
|
| Spike Glycoprotein, Coronavirus | 6 | 2024 | 184 | 0.540 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2021 | 713 | 0.490 |
Why?
|
| Body Fluids | 3 | 2019 | 48 | 0.470 |
Why?
|
| Virus Replication | 4 | 2024 | 602 | 0.420 |
Why?
|
| Dengue | 2 | 2024 | 110 | 0.400 |
Why?
|
| Dengue Virus | 2 | 2024 | 124 | 0.390 |
Why?
|
| Trypanosoma cruzi | 3 | 2024 | 228 | 0.380 |
Why?
|
| Animals | 14 | 2024 | 33870 | 0.350 |
Why?
|
| Vero Cells | 2 | 2021 | 111 | 0.350 |
Why?
|
| Insect Vectors | 3 | 2024 | 109 | 0.350 |
Why?
|
| Antibodies, Viral | 6 | 2023 | 1135 | 0.300 |
Why?
|
| Communicable Diseases | 2 | 2022 | 163 | 0.290 |
Why?
|
| Humans | 28 | 2024 | 121793 | 0.280 |
Why?
|
| Mice | 6 | 2024 | 17624 | 0.240 |
Why?
|
| Vimentin | 1 | 2024 | 65 | 0.220 |
Why?
|
| Tumor Necrosis Factors | 1 | 2023 | 12 | 0.220 |
Why?
|
| Genome, Viral | 1 | 2024 | 171 | 0.220 |
Why?
|
| Containment of Biohazards | 1 | 2023 | 5 | 0.210 |
Why?
|
| Travel | 1 | 2024 | 117 | 0.210 |
Why?
|
| Substance P | 1 | 2022 | 34 | 0.210 |
Why?
|
| Chemokines | 1 | 2023 | 137 | 0.210 |
Why?
|
| Lyme Disease | 1 | 2022 | 32 | 0.200 |
Why?
|
| Interleukins | 1 | 2023 | 116 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 5 | 2023 | 459 | 0.190 |
Why?
|
| Introduced Species | 1 | 2021 | 22 | 0.190 |
Why?
|
| Virus Inactivation | 1 | 2021 | 9 | 0.190 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 90 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 813 | 0.180 |
Why?
|
| Culicidae | 1 | 2021 | 65 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2021 | 170 | 0.170 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 422 | 0.170 |
Why?
|
| United States | 5 | 2022 | 10413 | 0.160 |
Why?
|
| HIV Seroprevalence | 1 | 2019 | 9 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2022 | 280 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 37 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2024 | 983 | 0.150 |
Why?
|
| Viral Vaccines | 1 | 2021 | 324 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2022 | 1365 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2019 | 269 | 0.150 |
Why?
|
| Zika Virus | 1 | 2019 | 135 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2019 | 384 | 0.140 |
Why?
|
| Arachnid Vectors | 1 | 2017 | 10 | 0.140 |
Why?
|
| Zika Virus Infection | 1 | 2019 | 160 | 0.140 |
Why?
|
| Middle Aged | 6 | 2024 | 25516 | 0.140 |
Why?
|
| Lassa Fever | 1 | 2015 | 7 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2019 | 1300 | 0.130 |
Why?
|
| Junin virus | 1 | 2015 | 1 | 0.130 |
Why?
|
| Arenaviruses, New World | 1 | 2015 | 3 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2021 | 508 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2019 | 1463 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1590 | 0.120 |
Why?
|
| Adult | 6 | 2022 | 28549 | 0.120 |
Why?
|
| Immunoglobulin G | 3 | 2023 | 769 | 0.120 |
Why?
|
| Public Health | 1 | 2017 | 250 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 1101 | 0.120 |
Why?
|
| Interferons | 1 | 2015 | 120 | 0.120 |
Why?
|
| Military Personnel | 1 | 2017 | 203 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2015 | 140 | 0.120 |
Why?
|
| Aged | 3 | 2022 | 18732 | 0.110 |
Why?
|
| Child | 4 | 2022 | 23789 | 0.110 |
Why?
|
| Belize | 2 | 2024 | 12 | 0.110 |
Why?
|
| Genotype | 1 | 2019 | 2483 | 0.110 |
Why?
|
| Female | 7 | 2021 | 64573 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1759 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2015 | 401 | 0.100 |
Why?
|
| Young Adult | 3 | 2022 | 8676 | 0.100 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2023 | 96 | 0.100 |
Why?
|
| Vaccines, Subunit | 2 | 2022 | 66 | 0.100 |
Why?
|
| Incidence | 1 | 2019 | 2962 | 0.090 |
Why?
|
| Male | 7 | 2021 | 59243 | 0.090 |
Why?
|
| Brain | 1 | 2022 | 2941 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2015 | 907 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 5773 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2021 | 5960 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4385 | 0.090 |
Why?
|
| Fever | 2 | 2022 | 295 | 0.090 |
Why?
|
| Phenotype | 1 | 2019 | 4200 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2023 | 1401 | 0.080 |
Why?
|
| Semen | 2 | 2019 | 71 | 0.080 |
Why?
|
| Saliva | 2 | 2019 | 113 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6275 | 0.070 |
Why?
|
| Adolescent | 3 | 2022 | 18773 | 0.070 |
Why?
|
| Texas | 3 | 2020 | 3431 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4306 | 0.060 |
Why?
|
| Nicaragua | 1 | 2024 | 26 | 0.060 |
Why?
|
| Mutation Rate | 1 | 2024 | 66 | 0.060 |
Why?
|
| Serogroup | 1 | 2024 | 49 | 0.060 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 208 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2021 | 3075 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 65 | 0.050 |
Why?
|
| Alum Compounds | 1 | 2022 | 41 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 2322 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 70 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 119 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2021 | 95 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 374 | 0.050 |
Why?
|
| Primates | 1 | 2021 | 80 | 0.050 |
Why?
|
| Proteome | 1 | 2022 | 231 | 0.050 |
Why?
|
| Haplotypes | 1 | 2022 | 507 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 376 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2021 | 285 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2021 | 161 | 0.040 |
Why?
|
| Rabbits | 1 | 2021 | 717 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 670 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 684 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 566 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2021 | 620 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 475 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 4623 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1561 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 772 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 175 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2021 | 1069 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1685 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 401 | 0.040 |
Why?
|
| Vagina | 1 | 2019 | 202 | 0.040 |
Why?
|
| Cochlear Nerve | 1 | 2015 | 11 | 0.030 |
Why?
|
| Lassa virus | 1 | 2015 | 20 | 0.030 |
Why?
|
| Sierra Leone | 1 | 2015 | 30 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 293 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 106 | 0.030 |
Why?
|
| Ear, Inner | 1 | 2015 | 52 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 259 | 0.030 |
Why?
|
| Microscopy | 1 | 2015 | 119 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1272 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 319 | 0.030 |
Why?
|
| Kidney | 1 | 2017 | 1343 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7045 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12177 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 13661 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 9718 | 0.010 |
Why?
|